Amir Heidari

Amir Heidari

Auto-generated profile, based on publicly available information

Amir Heidari

Department of Cardiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Case Reports in Medicine
Verified
Journal Article
Open access
AHAmir Heidari
Amir Heidari
NMNafise Mohamadizade
Nafise Mohamadizade
AHArman Hasanzade
Arman Hasanzade
MFMorteza Fazlekhoda
Morteza Fazlekhoda
Background: Lithium, commonly used in the treatment of bipolar disorders, is primarily known for causing neurological and renal side effects. However, cardiac side effects are rarely reported. Case Summary: We present a case of chronic lithium toxicity in an 80‐year‐old woman. The patient was admitted to the emergency room due to loss of consciousness. Initial evaluation revealed severe sinus bradycardia as a presentation of sinus node dysfunction on the electrocardiogram, prompting the insertion of a pacemaker. During her admission to the critical care unit, it was discovered that the patient had been undergoing long‐term lithium treatment without medical supervision. The serum lithium level confirmed lithium intoxication. Following the discontinuation of lithium, both neurological and cardiac manifestations of lithium toxicity resolved. After the pacemaker was removed, the patient was discharged in stable condition. Discussion: Lithium has a narrow therapeutic range, which can lead to toxicity in the absence of routine monitoring. Lithium toxicity can cause serious cardiac effects and rhythm disturbances that are often overlooked because these manifestations are rare. Cardiac manifestations include arrhythmias, bradycardia, collapse, hypotension, myocardial infarction, and even death. Additionally, lithium toxicity can present with various electrocardiographic abnormalities such as T‐wave inversion, sinoatrial block, PR interval prolongation, QT prolongation/dispersion, and ventricular tachyarrhythmias. Clinicians should be aware of the potential cardiac effects of lithium toxicity and consider it in patients undergoing lithium treatment. A thorough understanding of these manifestations is essential, as the wide range of symptoms can be misleading without adequate knowledge.

28 December 2024 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
MRMohammad Rostamzadeh
Mohammad Rostamzadeh
SGSholeh Ghasemi
Sholeh Ghasemi
AHAmir Heidari
Amir Heidari
MAMaytham Hameed Al-Qanbar
Maytham Hameed Al-Qanbar
MGMaedeh Golnavaz
Maedeh Golnavaz
RFReza Faramarzzadeh
Reza Faramarzzadeh
Introduction: Contrast-induced acute kidney injury (CI-AKI) imposes high costs and various complications on individuals and society. Considering that inflammation is a significant risk factor for CI-AKI incidence, the present research aimed to investigate the relationship between the systematic immune-inflammation (SII) index and the CI-AKI risk in cardiovascular patients using the systematic review and meta-analysis method. Materials and Methods: In the present study, ProQuest, PubMed, Embase, Web of Science, Cochrane, Scopus, and Google Scholar databases were used to search for articles published until October 16, 2024. Data analysis was conducted using the STATA 14 software, and tests with P values < 0.05 were considered statistically significant. Results: There was no significant association between the SII index and risk of CI-AKI in patients who underwent carotid artery angiography (OR: 1; 95% CI: 1, 1.01) or coronary angiography (OR: 1.96; 95% CI: 0.94, 4.11). However, in patients undergoing percutaneous coronary intervention (PCI) (OR: 1.01; 95% CI: 1, 1.02), high SII index levels increased the risk of CI-AKI. High SII index levels (OR: 1.01; 95% CI: 1.01, 1.02), higher ages (OR: 1.04; 95% CI: 1.02, 1.06), high-sensitivity C-reactive protein (hs-CRP) (OR: 1.01; 95% CI: 1, 1.02), hypertension (OR: 1.63; 95% CI: 1.31, 2.03), diabetes mellitus (OR: 1.73; 95% CI: 1.12, 2.68), neutrophil to lymphocyte ratio (NLR) (OR: 1.09; 95% CI: 1.01, 1.17), and neutrophil count (OR: 1.12; 95% CI: 1.08, 1.16) increased the risk of CI-AKI in cardiovascular patients. On the other hand, estimated glomerular filtration rate (eGFR) (OR: 0.98; 95% CI: 0.98, 0.99), lymphocyte count (OR: 0.47; 95% CI: 0.31, 0.71), and hemoglobin (OR: 0.97; 95% CI: 0.96, 0.98), albumin (OR: 0.96; 95% CI: 0.93, 0.99) in individuals with CIN were lower than those in the no-CIN group. Conclusion: High systemic immune-inflammation index levels, age, NLR, hs-CRP, hypertension, diabetes mellitus, and neutrophil count were among the risk factors of CI-AKI incidence in cardiovascular patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024604243) and Research Registry (UIN: reviewregistry1904) website.

28 March 2026 in Journal of Nephropathology
Verified
Journal Article
Open access
PDF file
MRMohammad Rostamzadeh
Mohammad Rostamzadeh
YAYaser Abolhasani
Yaser Abolhasani
AHAmir Heidari
Amir Heidari
ARAbdolmohammad Ranjbar
Abdolmohammad Ranjbar
AEAli Emadzadeh
Ali Emadzadeh
RFReza Faramarzzadeh
Reza Faramarzzadeh
Introduction: Chronic inflammation plays a significant role in cardiovascular disease (CVD)–related mortality among patients with chronic kidney disease (CKD). The neutrophil‑to‑albumin percentage ratio (NPAR) has emerged as an indicator of an individual’s inflammatory status. This study aimed to investigate the association between elevated NPAR and the risk of CVD mortality in patients with CKD. Materials and Methods: The study was conducted in accordance with the PRISMA reporting guidelines. Comprehensive searches were performed across the Cochrane Library, Scopus, Web of Science, Embase, and PubMed databases, as well as the Google Scholar search engine, up to 30 January 2026. All statistical analyses were carried out using STATA version 14. Results: Compared with lower NPAR values, elevated NPAR was associated with a higher risk of cardiovascular mortality (OR = 1.54; 95% CI: 1.33–1.78) and all‑cause mortality (OR = 1.62; 95% CI: 1.40–1.89) in patients with CKD. In addition, higher NPAR increased the risk of CVD‑related death among patients undergoing hemodialysis (OR = 1.66; 95% CI: 1.29–2.15) and peritoneal dialysis (OR = 1.56; 95% CI: 1.25–1.94). Furthermore, the third quartile of NPAR (OR = 1.44; 95% CI: 1.16–1.78), the fourth quartile (OR = 1.92; 95% CI: 1.61–2.30), the second tertile (OR = 1.38; 95% CI: 1.07–1.80), and the third tertile (OR = 1.97; 95% CI: 1.61–2.41) were all associated with increased CVD mortality compared with the lowest category. Elevated NPAR also increased the risk of CVD‑related mortality in both men (OR = 1.23; 95% CI: 1.04–1.45) and women (OR = 1.16; 95% CI: 1.08–1.24) with CKD. Conclusion: Higher NPAR levels were associated with an increased likelihood of cardiovascular and all‑cause mortality among individuals with CKD. As NPAR values rose, the risk of CVD‑related death increased correspondingly when compared with lower levels. In addition, cardiovascular mortality risk was greater in men than in women, and higher among patients receiving hemodialysis than those undergoing peritoneal dialysis. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420261304086) and Research Registry (UIN: reviewregistry2082) websites.

14 September 2025 in Journal of Nephropathology
Verified
Journal Article
Open access
PDF file
SBSaeid Bejarzehi
Saeid Bejarzehi
FVFatemeh Vahmani
Fatemeh Vahmani
AHAmir Heidari
Amir Heidari
FKFariba Jafari Khabaz
Fariba Jafari Khabaz
FBFaeze Shafie Bafti
Faeze Shafie Bafti
MRMohammad Rostamzadeh
Mohammad Rostamzadeh
Introduction: Due to the close association between chronic kidney disease (CKD) and cardiovascular disease (CVD), maintaining optimal cardiovascular health (CVH) may serve as a preventive strategy to reduce the risk of CKD and its related health burden. Therefore, this study aimed to investigate the association between Life’s Essential 8 (LE8) and the risk of CKD. Materials and Methods: This study systematically searched the Cochrane, Embase, PubMed, ProQuest, Web of Science, Scopus, and Google Scholar databases up to April 26, 2025. Data analysis was performed using IBM SPSS Statistics version 19 and STATA version 14. Results: An increase in the LE8 score was associated with a reduced risk of CKD, as indicated by the odds ratio (OR: 0.74, 95% CI: 0.67–0.82) and hazard ratio (HR: 0.60, 95% CI: 0.46–0.77). The protective effect of higher LE8 scores was observed across various subgroups: individuals aged 40–49 (OR: 0.81, 95% CI: 0.78–0.84), 50–59 (OR: 0.75, 95% CI: 0.60–0.94), males (OR: 0.81, 95% CI: 0.76–0.87), females (OR: 0.91, 95% CI: 0.87–0.95), and populations from the UK (OR: 0.60, 95% CI: 0.46–0.77), China (OR: 0.64, 95% CI: 0.63–0.65), and the USA (OR: 0.77, 95% CI: 0.72–0.81). Similarly, both cohort studies (OR: 0.66, 95% CI: 0.54–0.81) and cross-sectional studies (OR: 0.73, 95% CI: 0.66–0.81) confirmed this inverse association. Moreover, compared to low LE8 scores, moderate (OR: 0.58, 95% CI: 0.52–0.65) and high (OR: 0.43, 95% CI: 0.35–0.53) LE8 scores were significantly associated with reduced CKD risk. Conclusion: An increase in the LE8 score was associated with a greater reduction in the risk of CKD in older age groups compared to younger ones, and in men compared to women. Moreover, the higher the LE8 score, the lower the risk of developing CKD. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251043587) and Research Registry (UIN: reviewregistry2006) websites.

12 August 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
MMMohammad Parsa Mahjoob
Mohammad Parsa Mahjoob
MHMohammad HajiAghajani
Mohammad HajiAghajani
NMNafiseh Mohamadizadeh
Nafiseh Mohamadizadeh
RSRoxana Sadeghi
Roxana Sadeghi
AHAmir Heidari
Amir Heidari
MFMorteza Fazlekhoda
Morteza Fazlekhoda

1 January 2026 in Journal of Parathyroid Disease
Verified
Journal Article
Closed access
KSKianoush Saberi
Kianoush Saberi
AHAmir Heidari
Amir Heidari
MRMohammad Rostamzadeh
Mohammad Rostamzadeh
ARAbdolmohammad Ranjbar
Abdolmohammad Ranjbar
FNFaezeh Nesaei
Faezeh Nesaei
SSShahnaz Sharifi
Shahnaz Sharifi
Recent findings detected a dynamic, reciprocal relationship between bone remodeling and cardiac dysfunction, significantly influencing atherosclerosis pathogenesis. The bone-heart axis consists of bidirectional signaling of bone-derived factors and dysregulated mineral metabolism, which directly affect vascular calcification, endothelial function, and myocardial stress. Conversely, cardiac hormones and systemic inflammation modulate osteoclast/osteoblast activity. Critically, shared molecular pathways, like RANKL/RANK/OPG modulate both skeletal turnover and vascular inflammation/calcification. Pathological bone resorption releases calcium and matrix vesicles that nucleate vascular calcification, accelerating atherosclerotic plaque instability. Reimagining this axis emphasizes on osteo-immunological mechanisms with central role in cardiovascular disease progression, suggesting integrated therapeutic targets for atherosclerosis beyond traditional lipid-centric approaches.